Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1993-12-22
1997-09-30
Cunningham, Thomas M.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4241851, 435 693, 530350, 530395, 536 2372, A61K 39215
Patent
active
056723504
ABSTRACT:
Nucleic acid sequences encoding the Bovine Coronavirus E2 (or BCV S) and E3 (or BCV HE) structural glycoproteins and methods of producing these proteins, including recombinant expression, e.g., in mammalian or insect cells, are provided. The E2 and E3 proteins or antigenic fragments thereof are useful components for Bovine Coronavirus vaccines and methods of treatment.
REFERENCES:
patent: 3873422 (1975-03-01), Mebus
patent: 3914408 (1975-10-01), Mebus
patent: 3919412 (1975-11-01), Mebus
patent: 3919413 (1975-11-01), Mebus
patent: 4567042 (1986-01-01), Acree et al.
patent: 4567043 (1986-01-01), Acree et al.
patent: 4904468 (1990-02-01), Gill et al.
patent: 5013663 (1991-05-01), Acree et al.
Cuatrecasas, P., et al., Annual Review of Bicohemistry 40:359-378 (1971), "Affinity chromatography".
Burki, F., et al., J. Vet. Med. 33:241-252 (1986), "Reduction of rotavirus-, coronavirus, and E. coli -associated calf-diarrheas in a large-size dairy herd by means of dam vaccination with a triple-vaccine".
Deregt, D., et al., Adv. Exp. Med. Biol. 218:473-474 (1987), "Monoclonal antibodies to two bovine coronavirus glycoproteins neutralize virus infectivity."
Deregt, D., et al., Virology 161:410-420 (1987), "Monoclonal antibodies to bovine coronavirus: characteristics and topographical mapping of neutralizing epitopes on the E2 and E3 glycoproteins."
Lapps, W., et al., Virology 157:47-57 (1987), "Sequence analysis of the bovine nucleocapsid and matrix protein genes".
Heckert, R. A., et al., Am. Vet. Res. 52(5):700-708 (1991), "Mucosal and systemic antibody responses to bovine coronavirus structural proteins in experimentally challenge-exposed calves fed low or high amounts of colostral antibodies".
Mullaney, T. P., et al., Am. J. Vet. Res. 49(2):156-159 (Feb. 1988), "Humoral immune response of the bovine fetus to in utero vaccination with attenuated bovine coronavirus".
Murakami, T., et al., Jpn J. Vet. Sci. 48(2):237-245 (1986), "Protective effect of orally administered immunoglobulins against experimental calf diarrhea".
Nagy, E., et al., Virology 176:426-438 (1990), "cloning and expression of NDV Hemagglutinin-Neuraminidase cDNA in a baculovirus expression vector system".
Parker, M. D., et al., J. Virology 64(4):1625-1629 (Apr. 1990), "Expression and secretion of the bovine coronavirus hemagglutinin-esterase glycoprotein by insect cells infected with recombinant baculovirus".
Thomsen, D.R., et al., J. Cellular Biochem. 43:67-79 (1990), "Structure of O-glycosidically linked oligosaccharides synthesized by the insect cell line Sf9".
Van Wyke, K. L., et al., Virology 160:465-472 (1987), "Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neurominidase glycoprotein by a recombinant baculovirus".
Wathen, M.W., et al., J. Gen. Virology 70:2625-2635 (1989), "Characterization of a novel human respiratory syncytial virus chimeric FG glycoprotein expressed using a baculovirus vector".
Yoden, S., et al., Virology 173:615-623 (1989), "Expression of the peplomer glycoprotein of murine coronavirus JHM using a baculovirus vector".
Infectious Diseases and Medical Microbiology, A. I. Braude (ed.), pp. 552-553 W.B. Saunders Co., Philadelphia, Pa (1986).
de Groot et al., (1987) Adv. Exp. Med. Biol. 218:31-38.
Cavanagh (1983) J. gen. Virol. 64:2577-2583.
Cavanagh et al., (1984) Avian Pathology 13:573-583.
Mockett et al., (1984) J. gen. Virol. 65:2281-2286.
Tomley et al., (1987) J. gen. Virol. 68:2291-2298.
Niesters et al., (1986) Virus Res. 5:253-263.
Laude et al., (1986) J. gen Virol. 67:19-130.
Sturman et al., (1985) J. Virol. 56:904-911.
Dalziel et al., (1986) J. Virol. 59:463-471.
Talbot et al., (1984) Virology 132:250-260.
Bachmeier et al., (1984) Virology 132:261-270.
Wege et al., (1984) J. gen Virol. 65:1931-1942.
Schmidt et al., (1987) J. gen Virol. 68:47-56.
Makino et al., (1987) Proc. Natl. Acad. Sci. USA 84:6567-6571.
Dea et al., (1980) Am. J. Vet. Res. 41:30-38.
King et al., (1984) J. Virol. 42:700-707.
Hogue et al., (1984) J. Virol. 51:384-388.
King et al., (1985) Virus Res. 2:53-59.
Lapps et al., (1987) Virology 157:47-57.
Deregt et al., (1987) Virology 161:410-420.
Parker et al., (1989) J. gen. Virol. 70:155-164.
Collins et al., (1982) Virology 119:358-3712.
Deregt et al., (1987) J. gen. Virol. 68:2863-2877.
Fleming et al., (1986) J. Virol. 58:869-875.
Keck et al., (1988) Virus Res. 9:343-356.
Yoo et al., (1991) Virology 183:91-98.
Fields et al., eds., Fundamental Virology, Raven Press, New York, p. 514.
de Groot et al., (1987) J. gen. Virol. 68:2639-2646.
Young et al., (1983) Proc. Natl. Acad. Sci. USA 80:1194-119.
Babiuk Lorne A.
Cox Graham J.
Parker Michael D.
Cunningham Thomas M.
Veterinary Infectious Disease Organization
LandOfFree
Recombinant bovine coronavirus E2 and E3 polypeptides and vaccin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant bovine coronavirus E2 and E3 polypeptides and vaccin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant bovine coronavirus E2 and E3 polypeptides and vaccin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2255034